These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28808989)

  • 1. Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
    Pellizzari L; Facchinetti R; Corrà L; Sepe A; Fantin F; Fontana G; Zamboni M; Di Francesco V
    Aging Clin Exp Res; 2018 Jun; 30(6):605-608. PubMed ID: 28808989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A; Salazar-Sánchez L
    Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
    Hulot JS; Vantelon C; Urien S; Bouzamondo A; Mahé I; Ankri A; Montalescot G; Lechat P
    Ther Drug Monit; 2004 Jun; 26(3):305-10. PubMed ID: 15167633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.
    Dufour B; Toussaint-Hacquard M; Kearney-Schwartz A; Manckoundia MD; Laurain MC; Joly L; Deibener J; Wahl D; Lecompte T; Benetos A; Perret-Guillaume C
    J Nutr Health Aging; 2012 Jul; 16(7):647-52. PubMed ID: 22836708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
    Chamoun N; Ghanem H; Hachem A; Hariri E; Lteif C; Mansour H; Dimassi H; Zalloum R; Ghanem G
    BMC Pharmacol Toxicol; 2019 May; 20(1):27. PubMed ID: 31064405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level.
    Mahe I; Gouin-Thibault I; Drouet L; Simoneau G; Di Castillo H; Siguret V; Bergmann JF; Pautas E
    Drugs Aging; 2007; 24(1):63-71. PubMed ID: 17233548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
    Singer JP; Huang MY; Hui C; Blanc PD; Boettger RF; Golden J; Watkins K; Hoopes C; Leard LE
    J Heart Lung Transplant; 2010 Sep; 29(9):1009-13. PubMed ID: 20627627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
    Lee YR; Vega JA; Duong HN; Ballew A
    Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
    Ellis MH; Hadari R; Tchuvrero N; Shapira S; Kovlenko I; Kozmiakova M; Zissin R; Elis A
    Clin Appl Thromb Hemost; 2006 Apr; 12(2):199-204. PubMed ID: 16708122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.
    Berges A; Laporte S; Epinat M; Zufferey P; Alamartine E; Tranchand B; Decousus H; Mismetti P;
    Br J Clin Pharmacol; 2007 Oct; 64(4):428-38. PubMed ID: 17509040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
    Moten MA; Gaber AO; Putney D; Patel SJ
    Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.